The widespread use of aspirin for cardiovascular protection may carry unexpected implications for the 1.6 billion people worldwide experiencing hearing loss. This dual relationship challenges the conventional view of aspirin as universally beneficial, revealing dosage-dependent mechanisms that either protect or damage auditory function. Low-dose aspirin demonstrates protective effects against noise-induced and drug-related hearing damage through anti-inflammatory pathways that reduce cochlear oxidative stress. The drug's beneficial actions operate through cyclooxygenase-dependent mechanisms alongside newer pathways including Wnt signaling and nuclear factor kappa-B modulation. These protective mechanisms appear to shield delicate inner ear structures from inflammatory damage that typically follows acoustic trauma or exposure to ototoxic medications. However, higher aspirin doses trigger concerning reversible auditory changes including temporary hearing threshold shifts, tinnitus, and synaptic damage. These adverse effects stem from cochlear ischemia, excessive NMDA receptor activation, and disrupted prostaglandin signaling that impairs outer hair cell function through Prestin protein modulation. The research landscape suggests this dose-response relationship may explain conflicting clinical observations about aspirin's auditory effects. From a practical standpoint, millions of adults taking daily low-dose aspirin for cardiovascular protection may inadvertently receive modest hearing protection benefits. However, the therapeutic window appears narrow, with protective effects potentially shifting to harmful ones at higher doses. This finding represents incremental but important progress in understanding drug-induced hearing effects, though translation to clinical practice requires additional human studies defining optimal protective dosing thresholds.